Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase - Wikidata - wikimedia - TriplyDB

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

http://www.wikidata.org/entity/Q27704817

about

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN ALK: a tyrosine kinase target for cancer therapy.Discovery of a potent dual ALK and EGFR T790M inhibitor.ALK alterations and inhibition in lung cancer.Targeting ALK: Precision Medicine Takes on Drug Resistance.Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation.Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.The role of brigatinib in crizotinib-resistant non-small cell lung cancer.Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.Best Practices in Treatment Selection for Patients With Advanced NSCLC.Treating ALK-positive non-small cell lung cancer.ALK inhibitors, resistance development, clinical trials.Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.Novel organophosphorus aminopyrimidines as unique structural DNA-targeting membrane active inhibitors towards drug-resistant methicillin-resistant Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature Autochthonous murine models for the study of smoker and never-smoker associated lung cancers Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

P2860

Q33553447-85D2BE9A-E912-424B-95DF-5718DB0D8D75 Q37305906-5BF7EAA6-F4AB-450A-9BFD-499F7B607385 Q37518624-B0B25555-1AEC-4507-BC94-EBD4EB2594DF Q38702793-144E9672-B632-4B2C-9E1F-F2C2BD5A1EAD Q38820412-F6D83640-02D6-4018-A216-82244474A7B8 Q39103431-9D4888C2-1FCF-4D0E-BC6D-F4FD59B61355 Q39278116-881A7B16-159D-4782-AF7A-87F5BEFF9B87 Q42315652-CE41ACDB-A464-426F-9DA2-0FAF8FC60914 Q45068477-19276544-F495-459E-848D-E2791051213D Q47094795-0347079A-E8DD-40FF-8069-759B8E4BDC53 Q47599265-2080E842-EEEC-4D19-AAA5-552026DDB334 Q47777234-2B95701C-945B-4973-AB31-C42FEA57A727 Q48512265-0BB20644-0CF2-4A5B-B405-A4F0D6235CB5 Q52679023-13C95AAB-CFF8-41CC-A545-708C1863AD23 Q52814108-D8B48D21-1A4C-4CA0-BB83-AFF8EAABBA87 Q54967334-9889FBB9-2099-4861-AB18-6C06BC98E256 Q55262467-AC2C4542-DFE0-4729-909D-8E3D26FF032D Q55327976-0F2DABD3-2B78-482C-BF65-F306400CCF36 Q57137770-159629B7-B6D4-4061-9094-8D78240D397A Q58761533-38FE9115-782D-4707-9087-4D7D2FD6F53D Q58804389-C73F7F03-A197-4660-B2A9-187A0E3B7675 Q58804575-DC34A7CF-00DA-40D9-9370-3B6F095650AB Q59135403-6C0E26A8-6160-4080-8135-CE1DEA7E79E3

P2860

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

http://www.wikidata.org/entity/Q27704817

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@ast

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@en

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@nl

type

label

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@ast

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@en

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@nl

prefLabel

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@ast

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@en

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@nl

P1433

Q27704817-F71E7B5D-FFD5-4051-9A42-9FB7493358E3

P1476

Q27704817-4BFCD8D0-06E2-4688-9DC1-B7764966BD48

P2093

Q27704817-02B16C08-44C2-430A-8B78-9ABE9473D54D

Q27704817-0841C3EF-ABC2-4A8F-840F-1E7D9284B041

Q27704817-0D0978F3-4041-4D50-8612-CB6959974ED5

Q27704817-11E8A9EF-FA0C-403D-ABD0-751BDC481F71

Q27704817-2054191A-F67E-4D43-B5E6-CDC22B8C5F02

Q27704817-418D869F-D48E-4CF5-B834-335BD50139A0

Q27704817-47BBC9C7-60AB-4421-8BB9-BECFA50623F1

Q27704817-502E3362-3F93-4638-95D2-62D8E0AA489E

Q27704817-5B1DE195-69EB-432D-911B-CBB43314233C

Q27704817-5B67501E-709F-431A-AA41-023B81148A66

P304

Q27704817-008B56CD-1C0B-4479-A4CE-167A50D1E329

P31

Q27704817-EF5B3EE7-C2BC-4D47-9D11-30F4F024F33E

P3181

Q27704817-08062279-AA28-4722-840A-704AA9C57972

P356

Q27704817-9D91A992-B8AC-4E9C-98FA-C830150E6769

P407

Q27704817-C7168E96-EECB-4FDE-8849-C650A50914F8

P433

Q27704817-6538FF8E-4081-48A5-BFA8-2522B76BCC18

P478

Q27704817-C67D63A5-D330-4CB5-8EA8-4A46C25E0AF8

P577

Q27704817-B1AE2541-0A0D-41D6-8DE3-4C16252AC29C

P698

Q27704817-1489F271-7C52-4E7C-B827-B899F9AC4B8D

P3181

P356

ACS.JMEDCHEM.6B00306

P1433

Journal of Medicinal Chemistry

P1476

Discovery of Brigatinib (AP261 ...... of Anaplastic Lymphoma Kinase

@en

P2093

Angela Toms

http://www.w3.org/2001/XMLSchema#string

Anna Kohlmann

http://www.w3.org/2001/XMLSchema#string

David Dalgarno

http://www.w3.org/2001/XMLSchema#string

Dong Zou

http://www.w3.org/2001/XMLSchema#string

Feng Li

http://www.w3.org/2001/XMLSchema#string

Frank Wang

http://www.w3.org/2001/XMLSchema#string

Hyun Gyung Jang

http://www.w3.org/2001/XMLSchema#string

Jan Romero

http://www.w3.org/2001/XMLSchema#string

Jeffrey Keats

http://www.w3.org/2001/XMLSchema#string

Jiwei Qi

http://www.w3.org/2001/XMLSchema#string

P304

4948-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4616278

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/ACS.JMEDCHEM.6B00306

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27144831

http://www.w3.org/2001/XMLSchema#string